Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer.

por Foekens, J. A., Portengen, H., Look, M. P., van Putten, W. L., Thirion, B., Bontenbal, M., Klijn, J. G.
Publicado 1994

Effect of hormonal manipulation and doxorubicin administration on cell cycle kinetics of human breast cancer cells.

por Bontenbal, M., Sieuwerts, A. M., Klijn, J. G., Peters, H. A., Krijnen, H. L., Sonneveld, P., Foekens, J. A.
Publicado 1989

Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group.

por Bontenbal, M., Andersson, M., Wildiers, J., Cocconi, G., Jassem, J., Paridaens, R., Rotmensz, N., Sylvester, R., Mouridsen, H. T., Klijn, J. G., van Oosterom, A. T.
Publicado 1998

Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cance...

por Bontenbal, M., Foekens, J. A., Lamberts, S. W., de Jong, F. H., van Putten, W. L., Braun, H. J., Burghouts, J. T., van der Linden, G. H., Klijn, J. G.
Publicado 1998

Efficacy of high-dose alkylating chemotherapy in the adjuvant treatment of HER2/neu-negative primary breast cancer: update of the Dutch randomized trial

por Rodenhuis, S, Bontenbal, M, Beex, LVAM, Smit, WM, Nooij, MA, Voest, EE, Wall, E van der, Hupperets, P, Tinteren, Harm van, Peterse, HL, Vijver, MJ van de, Vries, EGE de
Publicado 2005

Molecular subtypes of breast cancer and amplification of topoisomerase IIα: predictive role in dose intensive adjuvant chemotherapy

por Hannemann, J, Kristel, P, van Tinteren, H, Bontenbal, M, van Hoesel, Q G C M, Smit, W M, Nooij, M A, Voest, E E, van der Wall, E, Hupperets, P, de Vries, E G E, Rodenhuis, S, van de Vijver, M J
Publicado 2006